Lactate receptor, HCAR1, in neonatal hypoxic-ischemic encephalopathy

Burnsed, J. C.; June, A.; Marlicz, M.; Zucker, E.; Kain-Kuzniewski, E.; Mulhern, H.; Maharaj, L.; Sun, C.; Sun, H.; Joshi, S.; Kapur, J.

doi:10.1101/2025.09.16.676275

bioRxiv · 10.1101/2025.09.16.676275

Lactate receptor, HCAR1, in neonatal hypoxic-ischemic encephalopathy

Burnsed, J. C.·June, A.·Marlicz, M.·Zucker, E.·Kain-Kuzniewski, E.·Mulhern, H.·Maharaj, L.·Sun, C.·Sun, H.·Joshi, S.·Kapur, J.

View original source ↗Export metadata ↓

Abstract

IntroductionHydroxycarboxylic acid receptor 1 (HCAR1) is a G-protein coupled receptor for lactate that is expressed in the brain and plays a role in neuronal excitability, angiogenesis, and repair after injury. Hypoxic-ischemic encephalopathy (HIE) is the most common cause of brain injury and seizures in term neonates. The goal of this study was to describe HCAR1 expression and function in the neonatal brain and further understand its role in HIE. MethodsHCAR1 expression was measured using qRT-PCR in developing mice (postnatal day (p)10, 20, 30, 50). Electrophysiology was used to measure neuronal properties and spontaneous excitatory postsynaptic currents (sEPSC) in hippocampal principal neurons from HCAR1 knockout and wildtype mice when exposed to lactate. Then, p10 HCAR1 knockout and wildtype mice were exposed to hypoxia-ischemia (HI) and placed on electroencephalography (EEG) to compare seizure burden. HCAR1 expression after neonatal HI was measured with PCR. ResultsHCAR1 is expressed at p10 at similar levels to adults (n=6/group; 1-way ANOVA, p<0.0004). Lactate decreases amplitudes and sEPSC frequency in wildtype (p<0.0001, p<0.001) but not HCAR1 knockout mice (p<0.26, p=0.91). After HI, HCAR1 knockout mice have higher seizure burden (2318s in WT vs. 6497s in KO (p=0.04)) and behavioral seizure scores (4 in WT vs. 6 in KO (p<0.001)) than wildtypes. HCAR1 expression increased 24h post-HI but drops to below baseline at 48h post-HI. (n=3/group; p=0.02). ConclusionHCAR1 is expressed on neurons in the developing mouse brain. Lactate decreases neuronal excitability via HCAR1. HCAR1 is upregulated post-HI and mice lacking HCAR1 exhibit worse neonatal HI seizures. HighlightsO_LIHCAR1, a G-protein coupled, lactate receptor is expressed in the developing mouse brain C_LIO_LIHCAR1 is expressed on neurons in the neonatal mouse hippocampus C_LIO_LIHCAR1 is upregulated 24 hours after neonatal hypoxia-ischemia C_LIO_LIMice lacking HCAR1, exhibit worse neonatal hypoxic-ischemic seizures C_LI

Explore related subjects

neuroscience Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Burnsed, J. C., June, A., Marlicz, M., Zucker, E., Kain-Kuzniewski, E., Mulhern, H., Maharaj, L., Sun, C., Sun, H., Joshi, S., Kapur, J.. 2025-09-17. Lactate receptor, HCAR1, in neonatal hypoxic-ischemic encephalopathy. https://doi.org/10.1101/2025.09.16.676275

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗